Menu ×

HEALTHCARE & PHARMACEUTICAL

Thrombophilia Treatment Market Segmentation by Type (Factor V Leiden, Prothrombin 20210, Anti-Phospholipid Syndrome, and Others); by Drugs (Heparin, Warfarin, and Others); and by End User (Hospitals, Homecare, Specialty Centers, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Thrombophilia Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

·    July 2021- Sanofi highlighted new research from first-in-class investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura.

·    September 2020- Aspen Global Incorporated announced that it has divested its wholly owned subsidiary incorporated in Mauritius with Mylan Ireland Limited. The latter will acquire all the intellectual property related to Aspen’s Thrombosis Business in Europe1.

Global Thrombophilia Treatment Market Highlights 2022 – 2030

The global thrombophilia treatment market is estimated to garner a large amount of revenue by growing at a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing burden of obesity, and increasing prevalence of cardiovascular and trauma cases across the world. According to the World Health Organization, as of now, cardiovascular diseases account for about 17.9 million deaths, which is an estimated 32 percent of all the deaths globally.

Along with these, rise in consumption of alcohol and tobacco is predicted to add a risk of development of high blood pressure on veins leading to several thrombophilia complications, which in turn is expected to fuel the market growth in the upcoming years. Furthermore, escalating research and development spending in the field of hematological diseases, and government initiatives to raise awareness regarding blood disorders are projected to offer profitable opportunities to the market in the near future.

Thrombophilia Treatment Market

The market is segmented by end user into hospitals, homecare, specialty centers, and others, out of which, the hospitals segment is anticipated to hold the largest share in the global thrombophilia treatment market. This can be accounted to the high preference of patients to get their treatment by a healthcare professional operating in a hospital facility, and increase in the number of hospital admissions. Additionally, on the basis of type, the factor V Leiden segment is evaluated to acquire the largest share during the forecast period, which can be credited to the commonness of this type of thrombophilia among the general population. Apart from this, the upsurge in the number of people with genetic mutations around the globe is also assessed to drive growth to the market segment in the imminent time.  CLICK TO DOWNLOAD SAMPLE REPORT  

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Thrombophilia Treatment Market Regional Synopsis

On the basis of geographical analysis, the global thrombophilia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing investments for improving healthcare infrastructure, and larger patient pool in the region. Moreover, the market in North America is expected to occupy the largest share during the forecast period ascribing to the rising demand for progressive treatment options, and early adoption of technologies, especially in the United States. In addition, increasing geriatric population, and growing collaboration of domestic and international companies for awareness campaigns are also predicted to boost the region’s market growth in the coming years. As per the data given by Rural Health Information Hub, there are more than 46 million adults aged 65 years or older living in the United States as of 2019. By 2050, this number is anticipated to reach almost 90 million.

Thrombophilia Treatment Market

The global thrombophilia treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global thrombophilia treatment market includes the following segments:

By Type

  • Factor V Leiden
  • Prothrombin 20210
  • Anti-Phospholipid Syndrome
  • Others

By Drugs

  • Heparin
  • Warfarin
  • Others

By End User

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Growth Drivers

  • Growing Burden of Obesity Across the Globe
  • Increasing Prevalence of Cardiovascular and Trauma Cases Worldwide

Challenges

  • Poor Reimbursement Policies Provided by Government

Top Featured Companies Dominating the Market

  • Sanofi SA
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Pfizer, Inc.
  • Aspen Pharmacare Holdings Limited
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Novartis AG
  • OPOCRIN S.P.A
  • SARIA SE & Co. KG

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved